Novo Nordisk(US:NVO) Globenewswireยท2025-05-06 12:00Core Insights - Novo Nordisk is set to present new data on semaglutide at the 32nd European Congress on Obesity (ECO) from May 11-14, 2025, highlighting its impact on metabolic and cardiovascular health [1][2][4] - The data will include real-world evidence studies and analyses from the SELECT trial, demonstrating semaglutide's early cardiovascular benefits and its role in treating obesity and related conditions [1][2][4] Company Overview - Novo Nordisk is a leading global healthcare company focused on chronic diseases, particularly diabetes, and has a strong commitment to addressing obesity through innovative treatments [11] - The company has invested significantly in research and development to enhance understanding and treatment of obesity, with semaglutide showing potential benefits beyond weight loss [2][4][7] Product Information - Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that has been tested in various clinical programs for cardiometabolic diseases, with over 33 million patient-years of cumulative exposure since 2018 [7][8] - It is marketed under the brand names Wegovy, Ozempic, and Rybelsus, with specific indications for weight management and cardiovascular risk reduction in adults and adolescents [8][9][10] Research and Data Presentation - The upcoming presentations at ECO will cover a range of topics, including the societal impacts of obesity treatment, the burden of obesity in adolescents, and the effectiveness of digital support solutions in enhancing weight loss [2][4][5] - Key abstracts will focus on the relationship between obesity and long-term comorbidities, the effectiveness of semaglutide in real-world settings, and the early clinical benefits observed in patients with cardiovascular disease [2][5][6]